Apraglutide
Also known as: FE 203799
An investigational long-acting GLP-2 analog for short bowel syndrome, given once weekly. Not approved; a confirmatory Phase 3 trial is required.
Last updated
Mechanism of Action
Apraglutide is a synthetic GLP-2 receptor agonist engineered with amino acid substitutions that slow renal clearance and increase plasma protein binding, extending its half-life enough for once-weekly dosing. Like native GLP-2, it acts on intestinal GLP-2 receptors to promote mucosal growth (villus height and crypt depth), intestinal blood flow and absorption of fluid, electrolytes and nutrients in patients with a shortened bowel.
- Half-life
- Long-acting; supports once-weekly dosing
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Studied for reducing parenteral support volume in short bowel syndrome with intestinal failure
- Improved fluid and energy absorption in Phase 2 metabolic balance studies
- Evaluated in the STARS Phase 3 trial in adults on parenteral support
Potential Side Effects
- Gastrointestinal symptoms such as abdominal pain and distension reported in trials
- Injection-site reactions
- Fluid and electrolyte shifts as parenteral support changes
- Long-term safety not yet established
Common Dosing
No approved dose; trial regimens have used once-weekly subcutaneous injection in adults with short bowel syndrome, with parenteral support adjusted by the study team.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
No documented stacking partners for Apraglutide yet.
- View
STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure
2026
- View
Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial
2022